Fibrin and Platelet-targeting Thrombolytic Drug
Exhibitor: CENTER FOR BIOMEDICAL RESEARCH AND DEVELOPMENT, NCKU
Booth No: N516
Characteristic
The current thrombolytic therapy or percutaneous coronary intervention (PCI) needs to be combined with anti-platelet drugs for subsequent restenosis or recurrent thrombosis. Antithrombotic drugs in the market are associated with significant bleeding risk and thrombocytopenia. We now have successfully developed a novel antithrombotic drug without these side effects.
Other Products
Highest Rated Products